Clinical Trials Logo

Malignant Solid Neoplasm clinical trials

View clinical trials related to Malignant Solid Neoplasm.

Filter by:

NCT ID: NCT06414278 Recruiting - Clinical trials for Malignant Solid Neoplasm

Evaluation of Early Identification of Cognitive Side Effects of Immunotherapy

Start date: February 8, 2024
Phase:
Study type: Observational

This clinical trial evaluates the use of a tool kit, Stress, Affect, Language and Speech Analysis (SALSA), for early identification of cognitive side effects of immunotherapy compared to the standard of care assessment.

NCT ID: NCT06410209 Not yet recruiting - Clinical trials for Malignant Solid Neoplasm

A Culturally-Tailored Mobile Health and Social Media Physical Activity Intervention for Improving Physical Activity in Hispanic or Latino/Latina Adolescent and Young Adult Childhood Cancer Survivors, Walking Juntos Study

Start date: October 21, 2024
Phase: N/A
Study type: Interventional

This clinical trial tests the impact of a culturally-tailored home-based physical activity program on physical fitness in Hispanic or Latino/Latina adolescent and young adult (AYA) childhood cancer survivors. After treatment for cancer, some AYA survivors experience long-term effects from the cancer and its treatment including weight gain, fatigue and decreased physical fitness. Hispanic or Latino/Latina survivors may have a higher risk of these effects compared to non-Hispanics. Regular physical activity helps maintain healthy weight, energy levels and overall health. Participating in a culturally-tailored home-based physical activity program may help increase physical activity in Hispanic or Latino/Latina AYA childhood cancer survivors.

NCT ID: NCT06409000 Recruiting - Clinical trials for Malignant Solid Neoplasm

Evaluation of 3D Surface Scanning for Virtual-CT Based Radiation Therapy Treatment Planning

Start date: January 19, 2021
Phase:
Study type: Observational

This study evaluates if three dimensional (3D) surface images can be used instead of the standard computed tomography (CT) scans for treatment planning in electron radiation therapy. 3D scanning has previously been used by several groups to design patient-specific devices to be 3D printed, and as has shown excellent agreement with CT obtained surfaces. Using 3D surface imaging instead of x-ray based CT, benefits include: no ionizing radiation used to produce images, shorter time between patient consultation and treatment, and ability to produce and evaluate patient-specific devices for electron therapy earlier in the treatment planning process. This study may help researchers learn how 3D surface scanning may be used to produce a virtual CT image of patient surfaces, and accurately replace traditional planning CT for treatment planning of electron based radiation therapy.

NCT ID: NCT06395441 Not yet recruiting - Clinical trials for Malignant Solid Neoplasm

Wisconsin Ginseng for Decreasing Cancer Related Fatigue

Start date: June 1, 2024
Phase: Phase 3
Study type: Interventional

This phase III trial compares the effect of Wisconsin ginseng (panax quinquefolius) to placebo in patients with cancer that suffer from significant fatigue. Fatigue is among the most challenging symptoms to manage in patients with cancer, both on or off active treatment. This symptom complex meaningfully contributes to psychosocial distress, healthcare costs, and it also interferes with the delivery of anticancer therapies. American ginseng (Western ginseng) appears to be a promising appearing agent for treating cancer related fatigue. Western ginseng may reduce cancer-related fatigue.

NCT ID: NCT06360588 Active, not recruiting - Clinical trials for Malignant Solid Neoplasm

Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Loss (MATCH - Subprotocol Z1G)

Start date: June 19, 2018
Phase: Phase 2
Study type: Interventional

The phase II MATCH treatment trial tests how well copanlisib works to treat patients with cancer with PTEN loss. Copanlisib may stop the growth of tumor cells and may kill them by blocking some of the enzymes needed for cell growth.

NCT ID: NCT06353191 Recruiting - Clinical trials for Malignant Solid Neoplasm

Biomarkers to Predict Cancer Therapy-related Cardiotoxicity

Start date: May 3, 2019
Phase:
Study type: Observational

This study evaluates why some cancer patients but not others experience changes in heart function following treatment with chemotherapy.

NCT ID: NCT06351371 Active, not recruiting - Clinical trials for Malignant Solid Neoplasm

Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Mutations or Fusions (MATCH - Subprotocol K2)

Start date: June 19, 2018
Phase: Phase 2
Study type: Interventional

This phase II MATCH treatment trial tests how well erdafitinib (JNJ-42756493) works in treating patients with tumors that have FGFR mutations or fusions. Erdafitinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal FGFR protein that signals cancer cells to multiply. This may help keep cancer cells from growing and may kill them.

NCT ID: NCT06342453 Not yet recruiting - Clinical trials for Malignant Solid Neoplasm

Examining Arts as Therapy in Children With Cancer, CREATe Trial

Start date: May 1, 2024
Phase: N/A
Study type: Interventional

This clinical trial is being done to develop and test how well creative arts interventions (drawing, painting, making sculptures) compared to watching videos can affect symptoms and impact the quality of life in children with cancer. Creative arts mind-body interventions (CrA) are one type of complementary health interventions which have been associated with improved quality of life and reduced symptom burden among children with cancer. CrA is an ideal intervention for children with cancer due to the long hours spent in the hospital setting for treatments, the creativity and developmental focus of children, and their potential ability to communicate more easily through art than words. Researchers want to develop and test a CrA intervention to help improve symptoms and the quality of life of children with cancer.

NCT ID: NCT06322615 Recruiting - Clinical trials for Malignant Solid Neoplasm

Acupressure for Reducing Anxiety in Patients Undergoing Chemotherapy

Start date: August 8, 2023
Phase: N/A
Study type: Interventional

This clinical trial evaluates whether acupressure is helpful to reduce anxiety related to chemotherapy. Anxiety is experienced by many patients with cancer. Anxiety can be related to chemotherapy and may contribute to other symptoms, such as nausea and poor quality of life. Some patients diagnosed with cancer express interest in non-medicinal ways to manage symptoms. Acupressure is a noninvasive intervention that can be used for many different symptoms. Acupressure is well tolerated with minimal reports of adverse reactions, making it a good choice for patients with cancer. This study may help researchers learn whether acupressure is useful for managing anxiety in patients undergoing chemotherapy.

NCT ID: NCT06314672 Recruiting - Clinical trials for Malignant Solid Neoplasm

Outreach Project to Connect Underrepresented Populations to Clinical Trials at Ohio State University, CUSP2CT Project Trial

Start date: August 22, 2023
Phase: N/A
Study type: Interventional

This clinical trial tests the impact of the The Ohio State University Connecting Underrepresented Populations to Clinical Trials (CUSP2CT) project on clinical trial referrals and enrollment in racial/ethnic minorities. Progress in cancer prevention, detection and treatment can only be made by identifying and validating new and improved methods, compounds and modalities in clinical trials. Unfortunately, participation in clinical trials is not equal across all racial and ethnic groups, limiting progress against cancer in all population groups and further widening the disparity gap. To change this picture, concerted effort needs to be directed both at the communities at risk for being left out of trials and the systems that cause the disparities at all levels involved in accrual to clinical trials. The CUSP2CT project may have the potential to increase referral and accrual of racial/ethnic minorities to prevention/control and treatment trials.